Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 April 2007, Vol. 109, No. 7, pp. 2744-2750.
Prepublished online as a Blood First Edition Paper on November 28, 2006; DOI 10.1182/blood-2006-07-035006.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-07-035006v1
109/7/2744    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Douer, D.
Right arrow Articles by Avramis, V. I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Douer, D.
Right arrow Articles by Avramis, V. I
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted July 13, 2006
Accepted November 20, 2006

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults 55 years old or younger with newly diagnosed acute lymphoblastic leukemia

Dan Douer*, Henry Yampolsky, Lewis J Cohen, Kristy Watkins, Alexandra M Levine, Antonia P Periclou, and Vassilios I Avramis

Division of Hematology, Dept of Medicine, University of Southern California & Norris Comprehensive Cancer Center, Los Angeles, CA
Childrens Hospital Los Angeles, University of Southern California & Norris Comprehensive Cancer Center, Los Angeles, CA

* Corresponding author; email: douer_d{at}ccnt.hsc.usc.edu.

In contrast to that in children, pharmacokinetic, pharmacodynamic and safety information on pegaspargase in adults is very limited. We administered a single intravenous dose of pegaspargase (2000 IU/m2) as part of a standard front-line induction regimen to 25 adults, with newly diagnosed ALL, and obtained serum samples on several time points. The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/ml, the elimination half-life was 7 days and the volume of distribution was 2.43 L/m2. After the single dose, asparagine deamination was complete in all patients after 2 hours, and in 100%, 81% and 44% on days 14, 21, and 28 respectively. A pharmocodynamic correlation model showed minimal enzymatic activity of 0.2 IU/ml for optimal asparagine depletion. The kinetic POSTHOC analyses demonstrated enzymatic activity for 3 weeks or more. One patient developed neutralizing anti-asparaginase antibodies on day 22 post administration. Pegaspargase was well tolerated with few grade 3/4 side effects. No allergic reactions or pancreatitis were observed. In adults 55 years old or younger, pegaspargase produces a long duration of asparagine depletion, and can be given intravenously, with a safety profile that is similar to equivalent multiple doses of intramuscular E. coli asparaginase .


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. H. Goldstone, S. M. Richards, H. M. Lazarus, M. S. Tallman, G. Buck, A. K. Fielding, A. K. Burnett, R. Chopra, P. H. Wiernik, L. Foroni, et al.
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
Blood, February 15, 2008; 111(4): 1827 - 1833.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. M. Rowe and A. H. Goldstone
How I treat acute lymphocytic leukemia in adults
Blood, October 1, 2007; 110(7): 2268 - 2275.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020